Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 2
1966 1
1967 1
1968 1
1969 4
1971 3
1972 2
1973 1
1974 5
1975 2
1976 11
1977 8
1978 6
1979 12
1980 11
1981 17
1982 11
1983 17
1984 25
1985 23
1986 16
1987 30
1988 22
1989 28
1990 21
1991 30
1992 17
1993 24
1994 25
1995 24
1996 25
1997 22
1998 32
1999 26
2000 27
2001 21
2002 30
2003 39
2004 35
2005 45
2006 54
2007 51
2008 52
2009 78
2010 65
2011 72
2012 79
2013 75
2014 77
2015 100
2016 137
2017 119
2018 129
2019 108
2020 132
2021 174
2022 171
2023 112
2024 123
2025 161
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,475 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: sugimoto m. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
SGLT2 inhibition eliminates senescent cells and alleviates pathological aging.
Katsuumi G, Shimizu I, Suda M, Yoshida Y, Furihata T, Joki Y, Hsiao CL, Jiaqi L, Fujiki S, Abe M, Sugimoto M, Soga T, Minamino T. Katsuumi G, et al. Among authors: sugimoto m. Nat Aging. 2024 Jul;4(7):926-938. doi: 10.1038/s43587-024-00642-y. Epub 2024 May 30. Nat Aging. 2024. PMID: 38816549 Free PMC article.
Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice.
Suda M, Shimizu I, Katsuumi G, Yoshida Y, Hayashi Y, Ikegami R, Matsumoto N, Yoshida Y, Mikawa R, Katayama A, Wada J, Seki M, Suzuki Y, Iwama A, Nakagami H, Nagasawa A, Morishita R, Sugimoto M, Okuda S, Tsuchida M, Ozaki K, Nakanishi-Matsui M, Minamino T. Suda M, et al. Among authors: sugimoto m. Nat Aging. 2021 Dec;1(12):1117-1126. doi: 10.1038/s43587-021-00151-2. Epub 2021 Dec 10. Nat Aging. 2021. PMID: 37117524
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F. Clarke NW, et al. Among authors: sugimoto m. NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3. NEJM Evid. 2022. PMID: 38319800
Melanocortin therapies to resolve fibroblast-mediated diseases.
Khodeneva N, Sugimoto MA, Davan-Wetton CSA, Montero-Melendez T. Khodeneva N, et al. Among authors: sugimoto ma. Front Immunol. 2023 Jan 30;13:1084394. doi: 10.3389/fimmu.2022.1084394. eCollection 2022. Front Immunol. 2023. PMID: 36793548 Free PMC article. Review.
Japanese clinical practice guidelines for prostate cancer 2023.
Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T, Suzuki K, Shinmoto H, Tamada T, Inoue T, Sugimoto M, Takenaka A, Habuchi T, Ishikawa H, Mizowaki T, Saito S, Miyake H, Matsubara N, Nonomura N, Sakai H, Ito A, Ukimura O, Matsuyama H, Hara I. Kohjimoto Y, et al. Among authors: sugimoto m. Int J Urol. 2024 Nov;31(11):1180-1222. doi: 10.1111/iju.15545. Epub 2024 Jul 30. Int J Urol. 2024. PMID: 39078210
2,475 results